Lederfoline (Calcium Folinate)

Calcium folinate provides a reduced form of folic acid that enters the folate cycle downstream of dihydrofolate reductase inhibition. This restores tetrahydrofolate‑dependent reactions needed for DNA synthesis and cell division, allowing normal cells to recover while antifolate therapy continues.

The dose of Lederfoline is determined by the prescribing clinician based on the specific indication, patient weight, renal function and concurrent therapies. Healthcare professionals set the appropriate regimen and timing for each individual case.

Safety data for calcium folinate in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Lederfoline, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lederfoline (calcium folinate) is the standard folinic‑acid rescue agent and is preferred over high‑dose folic acid because it bypasses the dihydrofolate reductase block. Other agents, such as leucovorin calcium, are essentially the same molecule; alternatives like folic acid lack the same rapid cellular uptake and efficacy in rescue situations.

Lederfoline should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture and direct sunlight, and ensure the packaging remains sealed until use.

Lederfoline is administered orally in tablet or liquid form, as directed by the prescriber. The route of administration is oral, and the exact timing relative to other medications, such as methotrexate, is determined by the treating clinician.

Serious risks include severe allergic reactions such as anaphylaxis, rare skin conditions like Stevens‑Johnson syndrome, acute renal failure, pancytopenia and significant hepatic dysfunction. Patients should be monitored for any signs of these reactions and seek immediate medical attention if they occur.

Lederfoline should be avoided in patients with known hypersensitivity to calcium folinate or any of its excipients. Caution is also advised for individuals with severe renal or hepatic impairment, and it should only be used in pregnancy or lactation when clearly indicated by a healthcare professional.